SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Harrow Health, Inc. 8.625% Senior Notes due 2026 (HROWL) , forward earnings yield 7.00%. PEG 0.29 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 14.3
- PEG Ratio 0.29 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 37/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HROWL
Valuation Multiples
P/E (TTM)0.0
Forward P/E14.3
PEG Ratio0.29
Forward PEG0.29
P/B Ratio0.00
P/S Ratio3.46
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.14
Forward EPS (Est.)$1.79
Book Value / Share$0.00
Revenue / Share$7.41
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield7.00%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1.50 |
$19.94M |
$-19.09M |
-95.7% |
| 2017 |
$-0.60 |
$26.77M |
$-11.99M |
-44.8% |
| 2018 |
$0.61 |
$41.37M |
$14.63M |
35.3% |
| 2019 |
$0.01 |
$51.17M |
$168K |
0.3% |
| 2020 |
$-0.13 |
$48.87M |
$-3.36M |
-6.9% |
| 2021 |
$-0.69 |
$72.48M |
$-18.01M |
-24.8% |
| 2022 |
$-0.51 |
$88.6M |
$-14.09M |
-15.9% |
| 2023 |
$-0.75 |
$130.19M |
$-24.41M |
-18.7% |
| 2024 |
$-0.49 |
$199.61M |
$-17.48M |
-8.8% |
| 2025 |
$-0.14 |
$272.3M |
$-5.14M |
-1.9% |
